Omega Therapeutics (NASDAQ:OMGA) Rating Reiterated by HC Wainwright

Omega Therapeutics (NASDAQ:OMGA)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $12.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 383.87% from the stock’s current price.

OMGA has been the topic of a number of other research reports. Piper Sandler reaffirmed an “overweight” rating and set a $9.00 price target (down previously from $10.00) on shares of Omega Therapeutics in a research note on Wednesday, April 3rd. Chardan Capital decreased their price target on shares of Omega Therapeutics from $12.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, April 1st. Finally, Wedbush reaffirmed an “outperform” rating and set a $12.00 price target on shares of Omega Therapeutics in a research note on Thursday, January 4th.

Omega Therapeutics Price Performance

Shares of NASDAQ:OMGA opened at $2.48 on Tuesday. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.35 and a current ratio of 3.35. The firm has a fifty day moving average price of $3.27 and a 200 day moving average price of $2.95. Omega Therapeutics has a fifty-two week low of $1.30 and a fifty-two week high of $10.09. The firm has a market cap of $136.78 million, a price-to-earnings ratio of -1.37 and a beta of 1.83.

Omega Therapeutics (NASDAQ:OMGA) last issued its earnings results on Thursday, March 28th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. Omega Therapeutics had a negative net margin of 3,147.92% and a negative return on equity of 110.41%. The firm had revenue of $0.99 million during the quarter, compared to analyst estimates of $0.93 million. As a group, sell-side analysts expect that Omega Therapeutics will post -1.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omega Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in OMGA. 683 Capital Management LLC raised its stake in shares of Omega Therapeutics by 7.0% in the third quarter. 683 Capital Management LLC now owns 508,242 shares of the company’s stock valued at $1,093,000 after acquiring an additional 33,242 shares during the period. Murphy Pohlad Asset Management LLC purchased a new stake in shares of Omega Therapeutics in the fourth quarter valued at $50,000. Finally, Etfidea LLC purchased a new stake in shares of Omega Therapeutics in the fourth quarter valued at $39,000. Hedge funds and other institutional investors own 97.47% of the company’s stock.

About Omega Therapeutics

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury.